The end of this week has Groundhog’s Day vibes to it. Yesterday, I wrote about falling net prices, which is something that I’ve been writing about for years even though
I often act all exasperated when data emerges that shows that the net prices of medicines are going down, feigning frustration at the fact that there has been limited recognition
Merck’s Winrevair won FDA approval yesterday, giving the company the green light to begin selling a medicine that is expected to be a key pillar of the company’s future. The
It’s a big day for PDABs. Buckle up. *** The biggest news is probably Amgen’s suit against the state of Colorado that makes the case that the prescription drug affordability
Everyone loves talking about obesity medicines, so let’s talk about obesity medicine. By taking Friday off, I didn’t get a chance to highlight the news that CMS will -- officially
This is an important story from The Hill. Not because it’s insightful or even particularly good, but because I think it reflects a dangerous kind of conventional wisdom that is
The most-clicked link yesterday was to a study about the discount rates used in HTA calculations. You are all hopelessly geeky, and that warms my heart. Once upon a time,
This seems like a good time to remind the few folks who aren’t already tracking: Drug Channels’ Adam Fein is hosting his next webinar — on the impact of the
Reading Bob Herman’s new STAT piece about the newest PBM tactic -- something called “rebate credits” -- is kind of tough sledding. The source materials aren’t made available, so his
I know I said that Cost Curve would be off today, but there were three items that caught my eye yesterday that I wanted to make sure I shared before